Why the study?
Does type 1 EWS-FLI1 fusion status confer a prognostic advantage in patients with localized Ewing sarcoma treated with current COG protocols?
Population
132 patients with localized Ewing sarcoma family tumors diagnosed after 1994 and treated according to…
Comparison
Type 1 EWS-FLI1 fusion (exposure/biomarker) vs Non-type 1 EWS-FLI1 fusions
Design
Cohort
Follow-up
5 years
Authors
Loading...
Type 1 EWS-FLI1 status no longer predicts superior EFS/OS in localized Ewing sarcoma; challenges historical stratification and leaves open prospective validation.
Does type 1 EWS-FLI1 fusion status confer a prognostic advantage in patients with localized Ewing sarcoma treated with current COG protocols?
Current intensive treatment protocols for localized Ewing sarcoma have eliminated the historical prognostic disadvantage of non-type 1 EWS-FLI1 fusions.
Doorninck et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: